Wall Street analyst estimates for Biofrontera Inc. (BFRI): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.22 | ||
| 2026-08-13 | $-0.05 | $-0.10 | +52.4% |
| 2026-05-14 | $-0.41 | $-0.18 | -127.8% |
| 2026-03-19 | $0.50 | $0.20 | +156.4% |
| 2025-11-12 | $-0.59 | $-0.60 | +1.7% |
| 2025-08-13 | $-0.57 | $-0.45 | -26.7% |
| 2025-05-15 | $-0.47 | $-0.21 | -118.6% |
| 2025-03-21 | $-0.19 | $0.02 | -1050.0% |
Valuation Ratios
| Price / Book | 2.78 |
| EV / EBITDA | -4.17 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $26.2M | $18.8M | $24.1M | $28.7M | $34.1M | $37.3M | $41.7M |
| Cost of Revenue | $12.4M | $9.1M | $12.7M | $15.2M | $17.4M | $18.6M | $8.9M |
| Gross Profit | $13.8M | $9.8M | $11.4M | $13.5M | $16.6M | $18.7M | $32.8M |
| Research & Development | 0 | 0 | 0 | 0 | $77000 | $2.1M | $3.7M |
| Selling, General & Admin | $28.7M | $18.1M | $37.2M | $35.9M | $39.1M | $33.8M | $38.1M |
| Operating Expenses | $28.7M | $19.4M | $36.6M | $32.1M | $39.3M | $35.9M | $42.0M |
| Operating Income | -$14.9M | -$9.6M | -$25.2M | -$18.6M | -$22.7M | -$17.2M | -$9.1M |
| EBITDA | -$8.1M | -$7.5M | -$36.8M | $934000 | -$18.5M | -$14.4M | -$9.2M |
| Interest Expense | $2.2M | $2.9M | $360000 | $370000 | $600000 | $2.1M | $452000 |
| Pre-tax Income | -$10.9M | -$10.9M | -$37.7M | -$608000 | -$20.1M | -$17.7M | -$10.5M |
| Income Tax | $33000 | $64000 | $56000 | $32000 | $14000 | $22000 | $25000 |
| Net Income | -$11.0M | -$11.0M | -$37.7M | -$640000 | -$20.1M | -$17.8M | -$10.5M |
| EPS | $-18.09 | $-18.94 | $-44.10 | $-0.61 | $-13.02 | $-3.22 | $-1.04 |
| EPS (Diluted) | $-18.09 | $-18.94 | $-44.10 | $-0.61 | $-13.02 | $-3.22 | $-0.90 |
| Shares Outstanding (Diluted) | $607000 | $580000 | $855237 | $1.1M | $1.5M | $5.5M | $11.6M |
Price
| Price | $1.21 |
| Market Cap | $15M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AYTU · COCP · DWTX · EVGN · GELS · IMNN · PRPH
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of BFRI: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks